Indicate Solutions, S.L. was set up in 2016 to exploit and commercialise the IP generated by the INDICATE project . The INDICATE project (IN vitro DIagnostic CAncer TEst) was originally conceived in 2013 by Charles Lawrie of Biodonostia, and Luis Liz-Marzán and Marek Gzelczak of CIC biomaGUNE in Donostia-San Sebastián, Spain. They were joined by Thomas Schafer of Polymat in 2014 and later by Lourdes Basabe of UPV and Wolfgang Parak of the University of Marburg.
The concept has received over €1,164K in competitive funding and with this funding, we have taken this project from the blackboard (i.e. TRL1) to experimentally validating these concepts (i.e. TRL3/4), which had resulted in generation of EPO patent filing (EP2016/077267). Indicate Solutions has been granted an exclusive licence to exploit and commercialise this IP.
The INDICATE device concept is a handheld point-of-care (POC) companion diagnostic device to detect cancer-specific mutations from drop of blood (liquid biopsies).
Global liquid biopsy market will be $4.5 billion by 2020
Cancer liquid biopsy market has a five-year CAGR of 36.2%
Millions funded into companies already
2.78 million potential users worldwide for lung cancer alone
Unique selling points of INDICATE device:
- Single-use disposable
- No laboratory equipment/specialised personnel required
- Rapid (minutes) yes/no answer
- Platform technology rapidly adaptable to new indications including:
- personalised medicine (cancer), infectious disease, environmental monitoring, veterinary use, extreme environments etc.